Marinus Pharmaceuticals Inc
General ticker "MRNS" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $31.1M
Marinus Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -34.0%.
Estimated limits based on current volatility of 0.2%: low 0.55$, high 0.55$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.27$, 3.78$]
- 2024-12-30 to 2025-12-30 estimated range: [1.68$, 4.63$]
Financial Metrics affecting the MRNS estimates:
- Negative: Non-GAAP EPS, $ of -2.63 <= 0
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -20.78 <= 1.33
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of -1.91 <= -0.37
- Negative: Inventory ratio change, % of 6.92 > 1.11
- Negative: Investing cash flow per share, $ of -0.53 <= -0.07
Short-term MRNS quotes
Long-term MRNS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $15.35MM | $25.48MM | $30.99MM |
| Operating Expenses | $112.28MM | $138.27MM | $162.47MM |
| Operating Income | $-96.93MM | $-112.79MM | $-131.49MM |
| Non-Operating Income | $-1.84MM | $96.36MM | $-11.46MM |
| Interest Expense | $2.58MM | $10.67MM | $16.89MM |
| R&D Expense | $73.52MM | $79.91MM | $99.39MM |
| Income(Loss) | $-98.78MM | $-16.43MM | $-142.94MM |
| Taxes | $0.00MM | $3.39MM | $-1.54MM |
| Profit(Loss)* | $-101.66MM | $-19.82MM | $-141.41MM |
| Stockholders Equity | $53.49MM | $116.00MM | $16.77MM |
| Inventory | $9.31MM | $0.08MM | $2.41MM |
| Assets | $136.84MM | $259.52MM | $170.91MM |
| Operating Cash Flow | $-55.48MM | $-112.89MM | $-118.00MM |
| Capital expenditure | $2.89MM | $1.77MM | $0.12MM |
| Investing Cash Flow | $-1.42MM | $105.77MM | $-28.61MM |
| Financing Cash Flow | $41.31MM | $124.74MM | $26.63MM |
| Earnings Per Share** | $-2.77 | $-0.51 | $-2.63 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.